Indivior (NASDAQ:INDV) CFO Sells $1,357,200.00 in Stock

Indivior PLC (NASDAQ:INDV) CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the transaction, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. This represents a 11.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Price Performance

Indivior stock opened at $38.48 on Friday. The firm has a market capitalization of $4.69 billion, a PE ratio of 19.73 and a beta of 0.88. The company’s 50-day moving average is $35.44 and its 200-day moving average is $34.30. Indivior PLC has a fifty-two week low of $13.45 and a fifty-two week high of $41.00.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. The company had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. As a group, analysts expect that Indivior PLC will post 4.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $39.33.

Institutional Trading of Indivior

A number of institutional investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Indivior by 43.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock valued at $11,395,000 after buying an additional 96,177 shares during the period. Claret Asset Management Corp grew its position in Indivior by 5.4% during the third quarter. Claret Asset Management Corp now owns 784,588 shares of the company’s stock worth $18,916,000 after buying an additional 40,306 shares in the last quarter. Aberdeen Group plc acquired a new stake in Indivior during the third quarter worth approximately $3,875,000. Victory Capital Management Inc. acquired a new stake in Indivior during the third quarter worth approximately $19,437,000. Finally, Principal Financial Group Inc. acquired a new stake in Indivior during the third quarter worth approximately $1,696,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.